S18 Ep15: ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD
In today’s episode, we spoke with Paolo Tarantino, MD, PhD. Dr Tarantino is a breast medical oncologist and advanced fellow at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts.
In our exclusive interview, Dr Tarantino discussed practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting, including the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta) for first-line treatment of HER2-positive breast cancer based on findings from the phase 3 DESTINY-Breast09 trial…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.